The N-terminal of the Estrogen Receptor (ERalpha) Mediates Transcriptional Cross-talk with the Retinoic Acid Receptor in Human Breast Cancer Cells
Overview
Molecular Biology
Authors
Affiliations
Transcriptional cross-talk exists between the estrogen receptor (ERalpha) and retinoic acid receptor (RAR) pathways in human breast cancer cells. We have previously shown that re-expression of ERalpha in ER-negative cells stimulates the transcriptional and growth inhibitory effects of all-trans-retinoic acid (tRA) by a mechanism that is independent of the ER ligands estradiol and tamoxifen. In this study, we generated cell lines stably expressing ERalpha-deletion mutants to elucidate the mechanism whereby ERalpha modulates RAR transcriptional activity. Using RT-PCR and RNAse protection assays, we observed that expression of ERalpha suppresses basal expression of the RA-responsive gene RARbeta2, while allowing it to be strongly induced by tRA. Repression of basal RARbeta2 transcription was confirmed by transient expression of the reporter plasmid betaRE-tk-CAT, containing the RARbeta2 promoter. In the ERalpha-negative cells, on the other hand, transcription was only weakly induced by RA. We further determined that this effect of ERalpha on RARbeta induction required the N-terminal AF-1-containing region, including the DNA-binding domain, but was independent of the C-terminal ligand-binding domain. Consistent with these results, the ER agonist estradiol and the AF-2 antagonist 4-hydroxytamoxifen had no significant effect on betaRARE activity. Conversely, the full ER antagonist ICI 182,780, which blocks ERalpha AF-1 activity, was able to completely relieve repression of basal betaRARE activity. The effect of ERalpha is specific for RAR-mediated transcription and does not occur on promoters containing typical response elements for the Vitamin D or thyroid hormone receptors. Moreover, the cross-talk between ERalpha and RAR does not seem to be mediated by sequestration of a number of common co-regulators, suggesting a novel mechanism whereby the N-terminal region of ERalpha modulates the transcriptional activity of RAR.
Jimenez-Dominguez G, Ravel P, Jalaguier S, Cavailles V, Colinge J Sci Rep. 2021; 11(1):7272.
PMID: 33790340 PMC: 8012374. DOI: 10.1038/s41598-021-86544-0.
Jones B, Sealy R, Penkert R, Surman S, Birshtein B, Xu B Viral Immunol. 2020; 33(4):307-315.
PMID: 32105583 PMC: 7247044. DOI: 10.1089/vim.2019.0144.
Jones B, Penkert R, Surman S, Sealy R, Pelletier S, Xu B Cell Immunol. 2019; 346:103996.
PMID: 31703914 PMC: 7368653. DOI: 10.1016/j.cellimm.2019.103996.
Corley S, Tsai S, Wilkins M, Weickert C PLoS One. 2016; 11(12):e0166944.
PMID: 27992436 PMC: 5161508. DOI: 10.1371/journal.pone.0166944.
Yasar P, Ayaz G, Muyan M Sci Rep. 2016; 6:37808.
PMID: 27886276 PMC: 5122896. DOI: 10.1038/srep37808.